A Leerink analyst downgraded Bristol Myers Squibb, shifting its view from outperform to a more bearish stance amid skepticism about upcoming catalysts and pipeline timing. The report cited pipeline fears that could affect investor expectations for near-term execution. While the underlying clinical development and regulatory progress are separate from analyst sentiment, downgrades can rapidly influence trading and capital allocation, especially when investors are focused on specific near-term readouts. The update adds to the competitive pressure on large-cap pharma as investors demand clearer evidence for pipeline differentiation and timing certainty.